MedTrace Logo

A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

NCT04780841 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2022-05-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the ability of RDX013 to lower serum potassium in patients with chronic kidney disease with elevated serum potassium levels

Conditions

  • Hyperkalemia

Interventions

DRUG

RDX013

RDX013 is an experimental drug that is a potassium secretagogue

DRUG

Placebo

Placebo treatment that looks identical to experimental treatment

Sponsors & Collaborators

  • Ardelyx

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-11
Primary Completion
2021-12-28
Completion
2022-03-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04780841 on ClinicalTrials.gov